Gene
ANXA1
ANXA1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (21), Actionable biomarkers (2), Trial mentions (1), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ANXA1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
ANXA1 has 1 trial mention across 1 year. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 5 of 11,460 | 0.04% |
| 2022 | 0 of 8,285 | 0.00% | 15 of 13,598 | 0.11% |
| 2021 | 0 of 8,692 | 0.00% | 19 of 15,045 | 0.13% |
| 2020 | 0 of 7,640 | 0.00% | 6 of 14,459 | 0.04% |
| 2019 | 1 of 7,300 | 0.01% | 9 of 12,159 | 0.07% |
| 2018 | 0 of 6,927 | 0.00% | 4 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 11 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (21)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| ABclonal | Reagent supplier | Clinical validationAnalytical validation | 1 | October 10, 2025 |
| Thermo Scientific | Reagent supplier | Analytical validation | 1 | August 02, 2024 |
| Waters | Reagent supplier | Analytical validation | 1 | August 02, 2024 |
| BECKMAN COULTER | Context dependent | Clinical validationAnalytical validation | 3 | May 19, 2023 |
| ABCAM | Reagent supplier | Clinical validationAnalytical validation | 2 | December 01, 2021 |
Showing 5 of 21 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ARID1A oncogenic mutation + ANXA1 overexpression | TRASTUZUMAB | responsive | breast adenocarcinoma | Cancer Genome Interpreter |
| ARID1A amplification + ANXA1 overexpression | TRASTUZUMAB | responsive | breast adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (1)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03786627 | Trial eligibility (AACT) |
Target-disease associations (378)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 1-methylnicotinamide measurement | measurement | GWAS credible sets |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development - adrenal insufficiency due to CYP11A1 deficiency | cancer or benign tumor | Mouse knockout (IMPC) |
| ANE syndrome | endocrine system disease | Mouse knockout (IMPC) |
| Abnormal nasolacrimal system morphology | phenotype | GWAS credible sets |
Showing 5 of 378 associations.
Vendor sourcing (7)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.287T>G (p.L96R) alteration is located in exon 5 (coding exon 4) of the ANXA1 gene. This alteration results from a T to G substitution at nucleotide pos... | View ClinVar record SCV003556833.2 |
| Labcorp Holdings Inc. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001059727.2 |
| Mahidol University | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | for individuals without impaired LPC 1. Between the ages of 20 and 40 2. No history of LBP that interferes with activities of daily living and/or requir... | View trial NCT03786627 |
| Mahidol University | Trial sponsor | Mentioned in trial textTrial free-text mention | LPC1 | View trial NCT03786627 |
| National Taiwan University | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | for individuals without impaired LPC 1. Between the ages of 20 and 40 2. No history of LBP that interferes with activities of daily living and/or requir... | View trial NCT03786627 |
Showing 5 of 7 sourcing records.
Trial-cited literature (124)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Factors associated with a reduction in the preventive effect of intravenous dexamethasone on rebound pain after axillary brachial plexus block. | British journal of anaesthesia | 2025 | 3 |
| ITGB5-mediated biomechanical regulation in pancreatic ductal adenocarcinoma stroma impacts tumor progression and prognosis. | Journal of translational medicine | 2025 | 0 |
| Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment. | Cellular & molecular immunology | 2024 | 40 |
| Annexin levels in GCF determine the imbalance of periodontal inflammatory regulation. | Scientific reports | 2024 | 8 |
| Extracellular vesicles: A dive into their role in the tumor microenvironment and cancer progression. | Frontiers in cell and developmental biology | 2023 | 55 |
Showing 5 of 124 papers.
Literature-extracted relations (26)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Poly IC | Chemical | associate |
Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment. | 2024 |
| Creatinine | Chemical | positive_correlate |
Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. | 2020 |
| DOXORUBICIN | Chemical | positive_correlate |
Intraductal therapy of ductal carcinoma in situ: a presurgery study. | 2013 |
| Carcinoma, Pancreatic Ductal | Disease | associate |
ITGB5-mediated biomechanical regulation in pancreatic ductal adenocarcinoma stroma impacts tumor progression and prognosis. | 2025 |
| Neoplasms | Disease | associate |
ITGB5-mediated biomechanical regulation in pancreatic ductal adenocarcinoma stroma impacts tumor progression and prognosis. | 2025 |
Showing 5 of 26 relation assertions.
Organizations publishing (213)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 10 | 2013 to 2022 |
| Harvard Medical School | Academic | 7 | 2011 to 2021 |
| Mass General Brigham | Hospital | 6 | 2016 to 2021 |
| Istituti di Ricovero e Cura a Carattere Scientifico | Hospital | 5 | 2017 to 2021 |
| University of Milan | Academic | 5 | 2018 to 2021 |
Showing 5 of 213 organizations.
Where ANXA1 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
360 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.